Literature DB >> 22581515

Relationship between plasma metalloproteinase-9 levels and volume and severity of infarct in patients with acute ischemic stroke.

Recep Demir1, Hızır Ulvi, Lütfi Özel, Gökhan Özdemir, Metin Güzelcik, Recep Aygül.   

Abstract

Matrix metalloproteinases (MMP) constitute an endopeptidase family involved in various physiological and pathological processes. It was demonstrated that plasma MMP-9 level was increased in patients with acute ischemic stroke. In this study, it was investigated whether there was a relationship between the levels of plasma MMP-9 and the severity of stroke and infarct volume in patients with acute ischemic stroke. A total of 32 patients with acute ischemic stroke, (16 males and 16 females) and 30 healthy controls were included in the study. Plasma MMP-9 levels were measured using ELISA method. Computed tomography was performed at 48th hour and infarct volume was calculated using the Cavalieri method. The National Institute of Health Stroke Scale (NIHSS) was checked at baseline, 12, 24, and 48th hour. Plasma MMP-9 levels of the patient group at baseline, 12, 24, and 48th hour were found significantly higher compared to the control group (p < 0.05). An important correlation between MMP-9 levels and the infarct volume was observed at baseline, 12, 24, and 48th hour (p < 0.001). Furthermore, a positive correlation was recorded between plasma MMP-9 levels and NIHSS scores at baseline, 12, 24, and 48th hour (p < 0.001). Plasma MMP-9 levels of those of suffering medium and heavy damages were found significantly higher when compared to those of having slight damage (p < 0.05). A significant relationship was also observed between infarct volumes and neurological deficits (p < 0.05). Plasma MMP-9 levels of the patients at 48th hour were found to be significantly lower in recovered patients compared to those who did not improved or worsened (p < 0.05). A positive correlation was recorded between the infarct volume and infarct progression (p < 0.05). In conclusion, this study showed that plasma MMP-9 level substantially increased during the acute period of ischemic cerebrovascular disease and correlated with the severity of the disease and infarct volume. The definition of the exact role of plasma MMP-9 after ischemic stroke will have important diagnostic implications for stroke and for the development of therapeutic strategies aimed at modulating plasma MMP-9.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22581515     DOI: 10.1007/s13760-012-0067-4

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  16 in total

Review 1.  Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers.

Authors:  Wei Wang; Mingchang Li; Qianxue Chen; Jian Wang
Journal:  Mol Neurobiol       Date:  2014-11-04       Impact factor: 5.590

2.  Neutrophil-To-Lymphocyte Ratio Predicts 3-Month Outcome of Acute Ischemic Stroke.

Authors:  Sen Qun; Yan Tang; Jing Sun; Zhaoxia Liu; Juncang Wu; Ji Zhang; Jidong Guo; Zhiqiang Xu; Dan Zhang; Zhengxu Chen; Fuyong Hu; Xingshun Xu; Wei Ge
Journal:  Neurotox Res       Date:  2017-02-08       Impact factor: 3.911

3.  Inflammatory and metabolic markers and short-time outcome in patients with acute ischemic stroke in relation to TOAST subtypes.

Authors:  Marcio Francisco Lehmann; Ana Paula Kallaur; Sayonara Rangel Oliveira; Daniela Frizon Alfieri; Franciele Delongui; Johnathan de Sousa Parreira; Maria Caroline Martins de Araújo; Carolina Rossato; Jéssica Tavares de Almeida; Larissa Moliterno Pelegrino; Erick Frank Bragato; Ana Lucia Cruz Fürstenberger Lehmann; Helena Kaminami Morimoto; Marcell Alysson Batisti Lozovoy; Andrea Name Colado Simão; Damácio Ramon Kaimen-Maciel; Edna Maria Vissoci Reiche
Journal:  Metab Brain Dis       Date:  2015-09-11       Impact factor: 3.584

Review 4.  Hemorrhagic transformation after ischemic stroke in animals and humans.

Authors:  Glen C Jickling; DaZhi Liu; Boryana Stamova; Bradley P Ander; Xinhua Zhan; Aigang Lu; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-27       Impact factor: 6.200

Review 5.  Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS).

Authors:  Marta Lukaszewicz-Zając; Barbara Mroczko; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2013-12-24       Impact factor: 3.575

6.  Matrix Metalloprotease 3 Exacerbates Hemorrhagic Transformation and Worsens Functional Outcomes in Hyperglycemic Stroke.

Authors:  Sherif Hafez; Mohammed Abdelsaid; Sally El-Shafey; Maribeth H Johnson; Susan C Fagan; Adviye Ergul
Journal:  Stroke       Date:  2016-02-02       Impact factor: 7.914

7.  The serum levels of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction.

Authors:  Shu-Jin Wang; Zhong-Sen Qu; Qing-De Zhang; Liang Li; Feng Wang; Bin Zhang; Bang-Li Wu; Yu-Wu Zhao
Journal:  Int J Clin Exp Med       Date:  2015-08-15

8.  Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke.

Authors:  Chongke Zhong; Jingyuan Yang; Tan Xu; Tian Xu; Yanbo Peng; Aili Wang; Jinchao Wang; Hao Peng; Qunwei Li; Zhong Ju; Deqin Geng; Yonghong Zhang; Jiang He
Journal:  Neurology       Date:  2017-07-26       Impact factor: 9.910

Review 9.  Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS).

Authors:  Marta Łukaszewicz-Zając; Barbara Mroczko; Agnieszka Słowik
Journal:  J Neural Transm (Vienna)       Date:  2014-07-22       Impact factor: 3.575

10.  Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke.

Authors:  Shaheen E Lakhan; Annette Kirchgessner; Deborah Tepper; Aidan Leonard
Journal:  Front Neurol       Date:  2013-04-03       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.